Japan-based cell therapy company Innovacell is planning to end a drought of biotech IPOs on the Tokyo Stock Exchange next week, the business’ CEO has confirmed. | Japan-based cell therapy company ...

Gilead has penned a potential $1.5 billion synthetic lethality deal with a Chinese biotech. A cell therapy company could end ...

Tokyo stocks ended lower Monday, weighed down by selling after the release of weaker-than-expected Japanese gross domestic product da ...

Tokyo stocks ended mixed Thursday as investors locked in gains, after sending the Nikkei index to a record intraday high for ...

There is no recent news for this security. Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more CNBC delivered to your inbox Get this delivered to your ...

Next Generation Technology Group Inc., the first listing on the Tokyo Stock Exchange this year, jumped in its trading debut to boost expectations that sentiment may improve in Japan’s primary market ...

Tokyo’s Nikkei 225 share index jumped as much as 5% to a record on Monday after Japanese Prime Minister Sanae Takaichi’s governing party secured a two-thirds supermajority in a ...

Tokyo Metro shares surged 45% Wednesday as the company that runs Japan’s largest public transport system made its debut on the Tokyo Stock Exchange. The transport company’s initial public offering saw ...

In this renewal, several measures have been implemented to enhance market convenience, including an introduction of the closing auction session, a new service that distributes market information by ...